Earnings Call
May 1, 2026
Q1 FY2026
EPS Estimate
-3.02
EPS Actual
-3.40
Post-Earnings Close
$45.37
Earnings Reaction
-1.2%
Moderna's first quarter 2026 results came in materially ahead of expectations, with revenue of $400 million representing a $300 million year-over-year increase and a significant beat versus the $50, $100 million range the company had implicitly signaled for the period. The outperformance was almost entirely driven by the timing of deliveries under Moderna's long-term strategic partnership with the UK government, specifically, product shipped for the UK's spring vaccination campaign targeting adults over 75 and high-risk populations. That delivery dynamic is important context: the UK runs both spring and fall campaigns, meaning a second delivery is expected in Q3/Q4, a structural tailwind that was absent from the prior year's international revenue base. Management reiterated full-year revenue growth of up to 10%, with geographic mix expected to be roughly 50/50 between the US and international markets, a meaningful shift from the heavily US-weighted mix of prior years.
Report generated on May 3, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full MRNA analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.